DSpace Repository

Prevalence of human papillomavirus genotypes in cervical cancer

Show simple item record

dc.contributor.author Chinchai T.
dc.contributor.author Chansaenroj J.
dc.contributor.author Swangvaree S.
dc.contributor.author Junyangdikul P.
dc.contributor.author Poovorawan Y.
dc.date.accessioned 2021-04-05T03:34:07Z
dc.date.available 2021-04-05T03:34:07Z
dc.date.issued 2012
dc.identifier.issn 1048891X
dc.identifier.other 2-s2.0-84863628026
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/14318
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863628026&doi=10.1097%2fIGC.0b013e318259d904&partnerID=40&md5=cf0450db22da58f7f09fd4cd224143e6
dc.description.abstract Background and Objective: Cervical cancer is the second most common female genital cancer worldwide. There is strong epidemiological and molecular evidence indicating that human papillomavirus (HPV) infection is a necessary event in the development of cervical intraepithelial lesion and subsequent invasive carcinoma. The aim of this study was to investigate the HPV genotype distribution and prevalence in cervical cancer of Thai women. Materials and Methods: One hundred fifty-five cervical cancer specimens were enrolled in this study. The HPV genotypes were determined by means of the combined use of a line probe assay (INNO-LiPA) and DNA chip methods. Results: Of the overall prevalence of HPV in the study group, 83.2% and 11.6% of the cases had single and multiple genotype infections, respectively. The most prevalent genotypes were HPV 16 (51%), followed by HPV 18 (20%), HPV 52 (10.3%), HPV 58 (5.8%), and HPV 33 (4.5%). All HPV genotypes found in this study could be classified as 13 highrisk HPV, 2 low-risk HPV, and 2 additional types. Of the specimens, 94.8% had at least one high-risk HPV genotype infection. Conclusion: As for the potential benefits of commercially available prophylactic vaccines to prevent HPV infection in Thailand, both vaccines (bivalent and quadrivalent) can protect from HPV-related cervical cancer in only approximately 71%. Therefore, screening programs such as routine Papanicolaou test, cytology, and HPV DNA detection are still essential for cervical cancer prevention. Moreover, future generations of HPV vaccines should also include the other most common genotypes and decrease the severe adverse effects reported at the present time. Copyright © 2012 by IGCS and ESGO.
dc.subject virus DNA
dc.subject adult
dc.subject aged
dc.subject article
dc.subject cancer prevention
dc.subject cancer staging
dc.subject cytology
dc.subject DNA microarray
dc.subject female
dc.subject genotype
dc.subject human
dc.subject Human papillomavirus type 16
dc.subject Human papillomavirus type 18
dc.subject Human papillomavirus type 33
dc.subject Human papillomavirus type 52
dc.subject Human papillomavirus type 58
dc.subject major clinical study
dc.subject nonhuman
dc.subject Papanicolaou test
dc.subject prevalence
dc.subject priority journal
dc.subject Thailand
dc.subject uterine cervix cancer
dc.subject verruca vulgaris
dc.subject Wart virus
dc.subject Adult
dc.subject Aged
dc.subject Aged, 80 and over
dc.subject Alphapapillomavirus
dc.subject Female
dc.subject Genotyping Techniques
dc.subject Humans
dc.subject Middle Aged
dc.subject Papillomavirus Infections
dc.subject Thailand
dc.subject Uterine Cervical Neoplasms
dc.title Prevalence of human papillomavirus genotypes in cervical cancer
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation International Journal of Gynecological Cancer. Vol 22, No.6 (2012), p.1063-1068
dc.identifier.doi 10.1097/IGC.0b013e318259d904


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics